Table 2.
Least Squares Mean Change from Baseline to Week 14 in SF-36 Subscale Scores and WOMAC Total and Subscale Scores in Duloxetine- and Placebo-Treated Patients
| Scale Itema | Duloxetine n=177 LS Mean (SE) |
Placebo n=176 LS Mean (SE) |
LS Mean Difference (95% CI) |
P-value |
|---|---|---|---|---|
| SF-36 score | ||||
| SF361 | 12.62 (1.27) | 6.23 (1.27) | 6.39 (2.85, 9.94) | <0.001 |
| SF362 | 11.44 (1.29) | 3.66 (1.30) | 7.78 (4.18, 11.39) | <0.001 |
| SF363 | 16.32 (1.22) | 9.63 (1.22) | 6.69 (3.30, 10.08) | <0.001 |
| SF364 | 5.58 (0.93) | 1.82 (0.94) | 3.77 (1.16, 6.37) | 0.005 |
| SF365 | 3.99 (1.04) | 3.16 (1.04) | 0.83 (−2.05, 3.72) | 0.570 |
| SF366 | 5.66 (1.14) | 2.54 (1.15) | 3.12 (−0.07, 6.31) | 0.055 |
| SF367 | 6.32 (1.27) | 0.70 (1.28) | 5.62 (2.06, 9.17) | 0.002 |
| SF368 | 3.02 (0.99) | 1.48 (0.99) | 1.55 (−1.21, 4.30) | 0.270 |
| WOMAC total score | −16.94 (0.90) | −9.99 (0.90) | −6.95 (−9.47, −4.44) | <0.001 |
| WOMAC pain subscale score | −3.90 (0.21) | −2.31 (0.21) | −1.59 (−2.17, −1.01) | <0.001 |
| PAIN1W | −0.81 (0.05) | −0.48 (0.05) | −0.33 (−0.47, −0.19) | <0.001 |
| PAIN2W | −1.01 (0.06) | −0.71 (0.06) | −0.30 (−0.46, −0.13) | <0.001 |
| PAIN3W | −0.63 (0.05) | −0.34 (0.05) | −0.29 (−0.42, −0.16) | <0.001 |
| PAIN4W | −0.79 (0.06) | −0.39 (0.06) | −0.40 (−0.57, −0.24) | <0.001 |
| PAIN5W | −0.62 (0.05) | −0.34 (0.05) | −0.28 (−0.41, −0.15) | <0.001 |
| WOMAC stiffness subscale score | −1.61 (0.09) | −0.91 (0.09) | −0.70 (−0.96, −0.44) | <0.001 |
| STIFF6W | −0.74 (0.05) | −0.38 (0.06) | −0.36 (−0.51, −0.20) | <0.001 |
| STIFF7W | −0.83 (0.05) | −0.53 (0.05) | −0.30 (−0.44, −0.16) | <0.001 |
| WOMAC physical function subscale score | −11.44 (0.65) | −6.76 (0.66) | −4.67 (−6.50, −2.85) | <0.001 |
| PFTN8W | −0.84 (0.06) | −0.58 (0.06) | −0.26 (−0.44, −0.09) | 0.004 |
| PFTN9W | −0.74 (0.06) | −0.45 (0.06) | −0.29 (−0.45, −0.13) | <0.001 |
| PFTN10W | −0.93 (0.06) | −0.60 (0.06) | −0.33 (−0.50, −0.16) | <0.001 |
| PFTN11W | −0.62 (0.05) | −0.33 (0.05) | −0.28 (−0.41, −0.15) | <0.001 |
| PFTN12W | −0.83 (0.05) | −0.45 (0.05) | −0.38 (−0.53, −0.23) | <0.001 |
| PFTN13W | −0.65 (0.05) | −0.41 (0.05) | −0.24 (−0.37, −0.11) | <0.001 |
| PFTN14W | −0.70 (0.05) | −0.36 (0.05) | −0.34 (−0.48, −0.20) | <0.001 |
| PFTN15W | −0.62 (0.05) | −0.41 (0.05) | −0.21 (−0.34, −0.07) | 0.003 |
| PFTN16W | −0.60 (0.05) | −0.35 (0.05) | −0.25 (−0.39, −0.11) | <0.001 |
| PFTN17W | −0.73 (0.04) | −0.42 (0.04) | −0.32 (−0.44, −0.19) | <0.001 |
| PFTN18W | −0.56 (0.05) | −0.32 (0.05) | −0.25 (-0.39, −0.11) | <0.001 |
| PFTN19W | −0.44 (0.04) | −0.30 (0.04) | −0.14 (−0.25, −0.03) | 0.014 |
| PFTN20W | −0.53 (0.05) | −0.26 (0.05) | −0.27 (−0.39, −0.14) | <0.001 |
| PFTN21W | −0.72 (0.06) | −0.49 (0.06) | −0.23 (−0.41, −0.05) | 0.012 |
| PFTN22W | −0.56 (0.04) | −0.35 (0.04) | −0.21 (−0.33, −0.09) | <0.001 |
| PFTN23W | −0.72 (0.06) | −0.47 (0.06) | −0.25 (−0.42, −0.08) | 0.005 |
| PFTN24W | −0.47 (0.04) | −0.22 (0.04) | −0.25 (−0.37, −0.13) | <0.001 |
Notes: aSee Table 1 for a description of each item. WOMAC scale items from Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833–1840. Copyright © 1996 Nicholas Bellamy. All Rights Reserved.28
Abbreviations: CI, confidence interval; LS, least squares; SE, standard error; SF-36, 36-item Short Form Survey; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.